Complexation behavior of antiestrogen drug tamoxifen citrate with natural and modified β-cyclodextrins

Journal of Inclusion Phenomena and Macrocyclic Chemistry

Volumn 57, Issue 1-4, 2007, Pages 651-655

  Bilensoy, Erem ^a   Doğan, Lale ^a   Şen, Murat ^a   Hıncal, Atilla ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Amphiphilic cyclodextrin; Anticancer efficacy; Characterization; DSC; FTIR; Inclusion complex; MTT assay; NMR; Tamoxifen citrate; CDC6; Cyclodextrin

Indexed keywords

EID: 34047189675     PISSN: 09230750     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10847-006-9268-x     Document Type: Conference Paper

References (17)

1. O'Reagan, R.M., Jordan, V.C.: The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators. Lancet Oncol. 3, 207-214(2002)
2. Pappas, S.G., Jordan, V.C.: Chemoprevention of breast cancer: current and future prospects. Cancer Metastasis Rev. 21, 311-321 (2002)
3. Powles, T.J.: Anti-oestrogenic chemoprevention of breast cancer- the need to progress. Eur. J. Cancer 39, 572-579 (2003)
4. Peters-Engl, C., Frank, W., Danmayr, E., Friedl, H.P., Leodolter, S., Medl, M.: Association between endometrial cancer and tamoxifen treatment of breast cancer. Breast Cancer Res. Treat. 54, 255-260 (1999)
5. Cohen, I.: Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol. Oncol. 94, 256-266 (2004)
6. de Lima, G.R., Facina, G., Shida, J.Y., Chein, M.B.C., Tanaka, P., Dardes, R.C., Jordan, V.C., Gebrim, L.H.: Effects of low dose tamoxifen on normal breast tissue from premenopausal women. Eur. J. Cancer 39, 891-898 (2003)
7. Albers, E., Müller, B.W.: Cyclodextrin derivatives in pharmaceuticals. CRC Crit. Rev. Ther. Drug Carrier Syst. 12(4), 311-337 (1995)
8. Loftsson, T., Masson, M., Brewster, M.E.: Self-association of cyclodextrins and cyclodextrin complexes. J. Pharm. Sci. 93(5), 1091-1099 (2004)
9. Duchene, D., Ponchel, G., Wouessidjewe, D.: Cyclodextrins in targeting. Applications to nanoparticles. Adv. Drug Deliv. Rev. 36, 29-40 (1999)
10. Memisoglu, E., Bochot, A., Şen, M., Özalp, M., Duchene, D., H?ncal, A.A.: Direct formation of nanospheres from amphiphilic β-cyclodextrin inclusion complexes. J. Pharm. Res. 20(1), 117-125 (2003)
11. Memisoglu, E., Bochot, A., Şen, M., Charon, D., Duchene, D., H?ncal, A.A.: Amphiphilic β-cyclodextrins modified on the primary face: synthesis, characterization and evaluation of their potential as novel excipients in the preparation of nanocapsules. J. Pharm. Sci. 91(5), 1214-1224 (2002).
12. Hedges, A.R.: Industrial applications of cyclodextrins. Chem. Rev. 98, 2035-2044 (1998).
13. Yang, X.H., Sladek, T.L., Liu, X., Butler, B.R., Froelich, C.J., Thor, A.D.: Reconstitutionof caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-inducedapoptosis. Cancer Res. 61, 348-354 (2001)
14. Hedges, A.R., Shieh, W.J.: Complexation in modified cyclodextrins compared with unmodified cyclodextrins. In: Duchene, D. (ed.) New Trends in Cyclodextrins and Derivatives. Editions de Santé, Paris (1991)
15. Schneider, H.J., Hackle, F., Rudiger, V.: NMR studies of cyclodextrins and cyclodextrin complexes. Chem. Rev. 98, 1755-1785 (1998).
16. Thompson, D.O.: Cyclodextrins as enabling excipients: their present and future use in pharmaceuticals. CRC Crit. Rev. Ther. Drug Carrier Syst. 14(1), 1-104 (1997).
17. Memisoglu-Bilensoy, E., Bochot, A., Trichard, L., Duchene, D., Hincal, A.A.: Amphiphilic cyclodextrins and microencapsulation. In: Benita, S. (ed.) Microencapsulation-2nd and Revised Edition, pp. 269-295, Taylor & Francis Ltd, New York, (2003)